Bayer increases its donations of medications for ebola patients to a total value of more than EUR 3.7 million

Bayer is expanding its aid donations for ebola patients in Liberia and Sierra Leone. The company is supplementing its previous donation of medications with a further delivery of the antibiotic ciprofloxacin to a value of EUR 1.15 million. This medication does not treat the ebola infection itself, but can be used for life-threatening secondary bacterial infections. Distribution to two clinics in Monrovia, the capital city of Liberia, and health centers in the surrounding area will be carried out through “action medeor – Das Medikamentenhilfswerk,” the largest Germany-based aid organization specializing in medicines. Bayer has already donated ciprofloxacin in various dosages and modes of administration to a value of approximately EUR 2.57 million to treat patients infected with the ebola virus free of charge in Sierra Leone and Liberia through the American organization “Direct Relief.” This donation of medication for treating African ebola patients with a total value of over EUR 3.7 million is one of the largest in Bayer’s history.

“We are again increasing our commitment to helping the people affected and making our contribution to stemming the spread of the ebola epidemic,” says Dr. Marijn Dekkers, Chairman of the Board of Management of Bayer AG. “With this donation, we are fulfilling our corporate social responsibility as a global health company.” The antibiotic ciprofloxacin can be used to treat bacterial secondary infections in patients weakened by ebola.

The company is also giving EUR 50,000 to “action medeor” to help finance the purchase of the protective clothing needed in two isolation wards that were set up in Monrovia at the end of October 2014. Bayer has also already donated EUR 25,000 to Caritas international for purchasing and distributing hand sanitizer in Liberia as a preventive measure.

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer’s products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2013, the Group employed 113,200 people and had sales of EUR 40.2 billion. Capital expenditures amounted to EUR 2.2 billion, R&D expenses to EUR 3.2 billion. For more information, go to www.bayer.com.

For social media users:
Visit Bayer on Facebook at: www.facebook.com/Bayer
Follow Bayer on Twitter at: twitter.com/Bayer

For more information go to www.bayer.com

Forward-Looking Statements
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports, which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.